Fabry disease and the skin: data from FOS, the Fabry outcome survey

被引:98
|
作者
Orteu, C. H. [1 ]
Jansen, T.
Lidove, O.
Jaussaud, R.
Hughes, D. A.
Pintos-Morell, G.
Ramaswami, U.
Parini, R.
Sunder-Plassman, G.
Beck, M.
Mehta, A. B.
机构
[1] Royal Free Hosp, Dept Dermatol, London NW3 2QG, England
[2] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
[3] Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany
[4] Hop Xavier Bichat, Dept Internal Med, Paris, France
[5] Hop Robert Debre, Dept Internal Med & Infect Dis, Reims, France
[6] Univ Hosp Germans Trias & Pujol, Dept Paediat, Badalona, Spain
[7] Addenbrookes Hosp, Dept Paediat, Cambridge, England
[8] Univ Milan, Dept Paediat, Monza, Italy
[9] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
[10] Johannes Gutenberg Univ Mainz, Mainz, Germany
关键词
angiokeratoma; Fabry disease; hyperhidrosis; hypohidrosis; lymphoedema; telangiectasia;
D O I
10.1111/j.1365-2133.2007.08002.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Fabry disease (also known as Anderson-Fabry disease) is a rare, X-linked lysosomal storage disorder that is characterized by accumulation of globotriaosylceramide throughout a range of tissues in the body. Objectives To ascertain the prevalence and nature of cutaneous manifestations in patients with Fabry disease and to relate these to the severity of systemic manifestations of the disease. Methods We have documented the dermatological features of this disease with reference to data from 714 patients (345 males, 369 females) registered on the Fabry Outcome Survey (FOS), a multicentre European database. Results We confirm that the commonest disease manifestation is angiokeratoma. Overall, 78% of males and 50% of females had one or more dermatological abnormality, the commonest being angiokeratoma (66% males, 36% females), hypohidrosis (53% males, 28% females), telangiectasia (23% males, 9% females) and lymphoedema (16% males, 6% females). We demonstrate for the first time that the presence of cutaneous vascular lesions correlates with the severity of the systemic manifestations of the disease (pain, renal failure, cardiac disease, premature cerebrovascular disease) as assessed by a severity scoring system. Although the condition is X linked, there is a surprisingly high prevalence of abnormalities in females. Conclusions The FOS database is a useful epidemiological tool in establishing the variety and relevance of cutaneous manifestations in Fabry disease. The present study confirms that the presence of dermatological manifestations appears to be a marker of greater severity of systemic disease, which emphasizes the importance of the dermatological assessment of these patients.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [31] Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey
    Mehta, A.
    Clarke, J. T. R.
    Giugliani, R.
    Elliott, P.
    Linhart, A.
    Beck, M.
    Sunder-Plassmann, G.
    JOURNAL OF MEDICAL GENETICS, 2009, 46 (08) : 548 - 552
  • [32] Growth and renal manifestations in children and adolescents with Fabry disease included in the Fabry outcome survey (FOS)
    Pintos-Morell, G.
    Ramaswami, U.
    Parini, R.
    Rohrbach, M.
    Kalkum, G.
    Beck, M.
    PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1675 - 1675
  • [33] RENAL MANIFESTATIONS AND GROWTH IN CHILDREN AND ADOLESCENTS WITH FABRY DISEASE INCLUDED IN THE FABRY OUTCOME SURVEY (FOS)
    Pintos-Morell, Guillem
    Ramaswami, Uma
    Parini, Rossella
    Rohrbach, Marianne
    Kalkum, Gisela
    Beck, Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 540 - 540
  • [34] White matter and pulvinar signal abnormalities in Fabry disease: data from the Fabry Outcome Survey
    Manara, R.
    Ginsberg, L.
    Severino, M.
    Valentine, A. R.
    Kendall, B.
    Clarke, J. T. R.
    Metha, A.
    Burlina, A. P.
    JOURNAL OF NEUROLOGY, 2007, 254 : 13 - 13
  • [35] Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)
    Hoffmann, B
    de Lorenzo, AG
    Mehta, A
    Beck, M
    Widmer, U
    Ricci, R
    JOURNAL OF MEDICAL GENETICS, 2005, 42 (03) : 247 - 252
  • [36] Cardiac involvement in Fabry disease patients: European experience from FOS-the Fabry outcome
    Linhart, A
    Kampmann, C
    Beck, M
    Dehout, F
    de Lorenzo, AG
    Mehta, A
    Ricci, R
    Widmer, U
    EUROPEAN HEART JOURNAL, 2003, 24 : 659 - 659
  • [37] Lyso-Gb3 as a biomarker for renal and cardiac involvement in Fabry disease: An analysis from the Fabry Outcome Survey (FOS)
    Ramaswami, Uma
    Altarescu, Gheona
    Fuller, Maria
    Nicholls, Kathleen
    Pintos-Morell, Guillem
    Torras, Joan
    Botha, Jaco
    Anagnostopoulou, Christina
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S103 - S104
  • [38] MEASURING PATIENT EXPERIENCES IN FABRY DISEASE: VALIDATION OF THE FABRY OUTCOME SURVEY (FOS) PAEDIATRIC HEALTH AND PAIN QUESTIONNAIRE
    Ramaswami, U.
    Stull, D. E.
    Parini, R.
    Pintos-Morell, G.
    Kalkum, G.
    Whybra, C.
    Rohrbach, M.
    Raluy, M.
    Beck, M.
    Wiklund, I
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S188 - S188
  • [39] Measuring patient experiences in fabry disease: validation of the Fabry Outcome Survey (FOS) paediatric health and pain questionnaire
    Ramaswami, Uma
    Whybra, Catharina
    Kalkum, Gisela
    Pintos Morell, Guillem
    Parini, Rosella
    Rohrbach, Marianne
    Wiklund, Ingela
    Raluy, Mireia
    Beck, Michael
    Stull, Donald
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (02) : S37 - S38
  • [40] Data from FOS-the Fabry outcome survey. Clinical features of children.
    Parini, R
    Beck, M
    Dehout, F
    Linhart, A
    de Lorenzo, AG
    Mehta, A
    Ricci, R
    Sunder-Plassmann, G
    Widmer, U
    Ramaswami, U
    PEDIATRIC RESEARCH, 2003, 54 (04) : 606 - 606